Novartis's Arcapta Neohaler reaches US market
This article was originally published in Scrip
Executive Summary
Novartis has launched its once-daily long-acting beta2 agonist (LABA) Arcapta Neohaler (indacaterol inhalation powder) in the US following its approval for chronic obstructive pulmonary disease (COPD) last July.